G. Deplanque

5.4k total citations · 1 hit paper
77 papers, 2.3k citations indexed

About

G. Deplanque is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Surgery. According to data from OpenAlex, G. Deplanque has authored 77 papers receiving a total of 2.3k indexed citations (citations by other indexed papers that have themselves been cited), including 53 papers in Oncology, 35 papers in Pulmonary and Respiratory Medicine and 16 papers in Surgery. Recurrent topics in G. Deplanque's work include Cancer Treatment and Pharmacology (20 papers), Colorectal Cancer Treatments and Studies (18 papers) and Pancreatic and Hepatic Oncology Research (11 papers). G. Deplanque is often cited by papers focused on Cancer Treatment and Pharmacology (20 papers), Colorectal Cancer Treatments and Studies (18 papers) and Pancreatic and Hepatic Oncology Research (11 papers). G. Deplanque collaborates with scholars based in France, United States and Switzerland. G. Deplanque's co-authors include Adrian L. Harris, Stéphane Oudard, Gwénaëlle Gravis, Josep Tabernero, Philippe Beuzeboc, Florence Joly, Stéphane Culine, R. Delva, Denis Pezet and Éric François and has published in prestigious journals such as Journal of Clinical Oncology, PLoS ONE and Cancer Research.

In The Last Decade

G. Deplanque

76 papers receiving 2.2k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Androgen Deprivation Therapy (ADT) Plus Docetaxel Versus ADT Alone in Metastatic Non castrate Prostate Cancer: Impact of Metastatic Burden and Long-term Survival Analysis of the Randomized Phase 3 GETUG-AFU15 Trial

2015 315 citations Gwénaëlle Gravis, R. Delva et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
G. Deplanque France	23	1.3k	812	633	542	225	77	2.3k
Guido Bellezza Italy	28	1.0k 0.8×	942 1.2×	830 1.3×	581 1.1×	247 1.1×	124	2.4k
Arlene Berman United States	22	1.3k 1.0×	474 0.6×	614 1.0×	534 1.0×	165 0.7×	47	2.4k
Ricardo Costa United States	22	1.1k 0.9×	601 0.7×	848 1.3×	540 1.0×	204 0.9×	82	2.2k
Björn Erikstein Norway	24	1.3k 1.0×	483 0.6×	859 1.4×	702 1.3×	141 0.6×	47	2.7k
Hervé Curé France	20	1.3k 1.0×	827 1.0×	279 0.4×	510 0.9×	218 1.0×	52	2.3k
Akihiko Shimomura Japan	22	1.1k 0.8×	536 0.7×	751 1.2×	537 1.0×	137 0.6×	132	2.0k
Nobuyuki Mizunuma Japan	23	1.5k 1.2×	530 0.7×	506 0.8×	367 0.7×	259 1.2×	133	2.0k
José Alejandro Pérez Fidalgo Spain	27	1.4k 1.1×	569 0.7×	1.3k 2.0×	853 1.6×	198 0.9×	136	2.9k
Volker Möbus Germany	26	1.2k 0.9×	312 0.4×	493 0.8×	587 1.1×	231 1.0×	117	2.2k
Aristidis Polyzos Greece	24	1.3k 1.0×	481 0.6×	718 1.1×	366 0.7×	275 1.2×	67	2.4k

Countries citing papers authored by G. Deplanque

Since Specialization

Citations

This map shows the geographic impact of G. Deplanque's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by G. Deplanque with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites G. Deplanque more than expected).

Fields of papers citing papers by G. Deplanque

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by G. Deplanque. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by G. Deplanque. The network helps show where G. Deplanque may publish in the future.

Co-authorship network of co-authors of G. Deplanque

This figure shows the co-authorship network connecting the top 25 collaborators of G. Deplanque. A scholar is included among the top collaborators of G. Deplanque based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with G. Deplanque. G. Deplanque is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

François, Éric, Laurent Mineur, G. Deplanque, et al.. (2020). Efficacy and Safety of Bevacizumab Combined With First-Line Chemotherapy in Elderly (≥75 Years) Patients With Metastatic Colorectal Cancer: A Real-World Study. Clinical Colorectal Cancer. 19(3). e100–e109. 6 indexed citations

Deplanque, G., Keyvan Shabafrouz, & Michel Obéid. (2017). Can local radiotherapy and IL-12 synergise to overcome the immunosuppressive tumor microenvironment and allow “in situ tumor vaccination”?. Cancer Immunology Immunotherapy. 66(7). 833–840. 20 indexed citations

Taı̈eb, Julien, Franck Bonnetain, Laurent Mineur, et al.. (2017). Three versus six months’ adjuvant oxaliplatin-based chemotherapy for patients with stage III colon cancer: Per-protocol, subgroups and long-lasting neuropathy results. Annals of Oncology. 28. v158–v158. 9 indexed citations

Deplanque, G., Radj Gervais, A. Vergnenègre, et al.. (2016). Doxycycline for prevention of erlotinib-induced rash in patients with non-small-cell lung cancer (NSCLC) after failure of first-line chemotherapy: A randomized, open-label trial. Journal of the American Academy of Dermatology. 74(6). 1077–1085. 27 indexed citations

Deplanque, G., Martin Demarchi, Mohamed Hebbar, et al.. (2015). A randomized, placebo-controlled phase III trial of masitinib plus gemcitabine in the treatment of advanced pancreatic cancer. Annals of Oncology. 26(6). 1194–1200. 78 indexed citations

François, Éric, Stéfano Kim, G. Deplanque, et al.. (2015). P-346 Non-interventional study in elderly patients with metastatic colorectal cancer treated with first line bevacizumab combined to chemotherapy in real life: The CASSIOPEE Study - Interim analysis on patients' characteristics. Annals of Oncology. 26. iv100–iv100. 1 indexed citations

Serdjebi, Cindy, Johan Gagnière, Jérôme Desrame, et al.. (2015). FFCD-1004 Clinical Trial: Impact of Cytidine Deaminase Activity on Clinical Outcome in Gemcitabine-Monotherapy Treated Patients. PLoS ONE. 10(8). e0135907–e0135907. 20 indexed citations

Pouessel, Damien, Sylvie Chevret, Frédéric Rolland, et al.. (2015). Standard or accelerated methotrexate, vinblastine, doxorubicin and cisplatin as neoadjuvant chemotherapy for locally advanced urothelial bladder cancer: Does dose intensity matter?. European Journal of Cancer. 54. 69–74. 11 indexed citations

Deplanque, G.. (2011). Cancers du rein. 6(3). 7.

10.

Mitry, Emmanuel, Pascal Hammel, G. Deplanque, et al.. (2010). Safety and activity of masitinib in combination with gemcitabine in patients with advanced pancreatic cancer. Cancer Chemotherapy and Pharmacology. 66(2). 395–403. 52 indexed citations

11.

Beuzeboc, Philippe, Eugéniu Banu, Éric Voog, et al.. (2007). Trastuzumab (T) combined with standard chemotherapy in HER+ metastatic bladder cancer (BC) patients: Interim safety results of a prospective randomized phase II study. Journal of Clinical Oncology. 25(18_suppl). 15565–15565. 12 indexed citations

12.

Viens, Patrice, Thierry Petit, Alejandro Yovine, et al.. (2006). A phase II study of a paclitaxel and oxaliplatin combination in platinum-sensitive recurrent advanced ovarian cancer patients. Annals of Oncology. 17(3). 429–436. 31 indexed citations

13.

Braybrooke, Jeremy, Andrew Slade, G. Deplanque, et al.. (2005). Phase I Study of MetXia-P450 Gene Therapy and Oral Cyclophosphamide for Patients with Advanced Breast Cancer or Melanoma. Clinical Cancer Research. 11(4). 1512–1520. 74 indexed citations

14.

Cals, L., Olivier Rixe, Éric François, et al.. (2004). Dose-finding study of weekly 24-h continuous infusion of 5-fluorouracil associated with alternating oxaliplatin or irinotecan in advanced colorectal cancer patients. Annals of Oncology. 15(7). 1018–1024. 23 indexed citations

15.

Viens, Patrice, Thomas Petit, Alejandro Yovine, et al.. (2004). Phase II trial of oxaliplatin (OXA) combined with paclitaxel (P) inplatinum + taxanes sensitive advanced ovarian cancer (AOC) patients: Final results. Journal of Clinical Oncology. 22(14_suppl). 5023–5023. 6 indexed citations

16.

Deplanque, G., Srinivasan Madhusudan, Philip H. Jones, et al.. (2004). Phase II trial of the antiangiogenic agent IM862 in metastatic renal cell carcinoma. British Journal of Cancer. 91(9). 1645–1650. 17 indexed citations

17.

Han, Chengcheng, Jeremy Braybrooke, G. Deplanque, et al.. (2003). Comparison of prognostic factors in patients in phase I trials of cytotoxic drugs vs new noncytotoxic agents. British Journal of Cancer. 89(7). 1166–1171. 37 indexed citations

18.

Céraline, Jocelyn, et al.. (2002). Anti-angiogenic effects of the thienopyridine SR 25989 in vitro and in vivo in a murine pulmonary metastasis model. British Journal of Cancer. 86(5). 803–810. 18 indexed citations

19.

Deplanque, G., et al.. (2000). Caffeine does not cause override of the G2/M block induced by UVc or gamma radiation in normal human skin fibroblasts. British Journal of Cancer. 83(3). 346–353. 10 indexed citations

20.

Deplanque, G. & Adrian L. Harris. (2000). Anti-angiogenic agents. European Journal of Cancer. 36(13). 1713–1724. 83 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact